196 related articles for article (PubMed ID: 17184669)
21. [Current status of 18F-FDG PET in predicting outcome of cancer therapy].
Gong HY; Yu JM
Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):577-80. PubMed ID: 16429617
[No Abstract] [Full Text] [Related]
22. Positron emission tomography imaging in nonsmall-cell lung cancer.
Erasmus JJ; Macapinlac HA; Swisher SG
Cancer; 2007 Nov; 110(10):2155-68. PubMed ID: 17896784
[TBL] [Abstract][Full Text] [Related]
23. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men.
Cerfolio RJ; Bryant AS; Scott E; Sharma M; Robert F; Spencer SA; Garver RI
Chest; 2006 Dec; 130(6):1796-802. PubMed ID: 17166999
[TBL] [Abstract][Full Text] [Related]
24. The effect of FDG-PET on the stage distribution of non-small cell lung cancer.
Morgensztern D; Goodgame B; Baggstrom MQ; Gao F; Govindan R
J Thorac Oncol; 2008 Feb; 3(2):135-9. PubMed ID: 18303433
[TBL] [Abstract][Full Text] [Related]
25. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
Hoekstra CJ; Stroobants SG; Smit EF; Vansteenkiste J; van Tinteren H; Postmus PE; Golding RP; Biesma B; Schramel FJ; van Zandwijk N; Lammertsma AA; Hoekstra OS
J Clin Oncol; 2005 Nov; 23(33):8362-70. PubMed ID: 16293866
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of different metabolic measurements with fluorine-18 fluorodeoxyglucose positron emission tomography in resectable non-small cell lung cancer: a two-center study.
de Jong WK; van der Heijden HF; Pruim J; Dalesio O; Oyen WJ; Groen HJ
J Thorac Oncol; 2007 Nov; 2(11):1007-12. PubMed ID: 17975491
[TBL] [Abstract][Full Text] [Related]
27. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.
Dooms C; Verbeken E; Stroobants S; Nackaerts K; De Leyn P; Vansteenkiste J
J Clin Oncol; 2008 Mar; 26(7):1128-34. PubMed ID: 18309948
[TBL] [Abstract][Full Text] [Related]
28. Utility of Routine PET Imaging to Predict Response and Survival After Induction Therapy for Non-Small Cell Lung Cancer.
Barnett SA; Downey RJ; Zheng J; Plourde G; Shen R; Chaft J; Akhurst T; Park BJ; Rusch VW
Ann Thorac Surg; 2016 Mar; 101(3):1052-9. PubMed ID: 26794896
[TBL] [Abstract][Full Text] [Related]
29. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.
Weber WA; Petersen V; Schmidt B; Tyndale-Hines L; Link T; Peschel C; Schwaiger M
J Clin Oncol; 2003 Jul; 21(14):2651-7. PubMed ID: 12860940
[TBL] [Abstract][Full Text] [Related]
30. Tumor fluoro-2-deoxy-D-glucose avidity on positron emission tomographic scan predicts mortality in patients with early-stage pure and mixed bronchioloalveolar carcinoma.
Raz DJ; Odisho AY; Franc BL; Jablons DM
J Thorac Cardiovasc Surg; 2006 Nov; 132(5):1189-95. PubMed ID: 17059942
[TBL] [Abstract][Full Text] [Related]
31. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA
Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202
[TBL] [Abstract][Full Text] [Related]
32. Restaging of mediastinal nodes with transbronchial needle aspiration after induction chemoradiation for locally advanced non-small cell lung cancer.
Kunst PW; Lee P; Paul MA; Senan S; Smit EF
J Thorac Oncol; 2007 Oct; 2(10):912-5. PubMed ID: 17909353
[TBL] [Abstract][Full Text] [Related]
33. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules.
Daniels CE; Lowe VJ; Aubry MC; Allen MS; Jett JR
Chest; 2007 Jan; 131(1):255-60. PubMed ID: 17218584
[TBL] [Abstract][Full Text] [Related]
34. [Value of 18F-fluorodeoxyglucose positron emission tomography imaging in staging of non-small cell lung cancer].
Guan Y; He S; Dong J
Zhonghua Yi Xue Za Zhi; 2001 Oct; 81(19):1180-3. PubMed ID: 11769705
[TBL] [Abstract][Full Text] [Related]
35. Endoscopic ultrasound-guided fine needle aspiration of mediastinal lymph node in patients with suspected lung cancer after positron emission tomography and computed tomography scans.
Eloubeidi MA; Cerfolio RJ; Chen VK; Desmond R; Syed S; Ojha B
Ann Thorac Surg; 2005 Jan; 79(1):263-8. PubMed ID: 15620955
[TBL] [Abstract][Full Text] [Related]
36. Treatment patterns and survival after 18F-fluorodeoxyglucose positron emission tomography/computed tomography-guided local consolidation therapy for oligometastatic non-small cell lung cancer: a two-center propensity score-matched analysis.
Song YQ; Wang N; Qiao Y; He L; Li X; Zhang XF; Yang QK; Wang RZ; He R; Wang CY; Ren YW; Li G; Wang TL
J Cancer Res Clin Oncol; 2020 Apr; 146(4):1021-1031. PubMed ID: 31980929
[TBL] [Abstract][Full Text] [Related]
37. Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage.
Collaud S; Stahel R; Inci I; Hillinger S; Schneiter D; Kestenholz P; Weder W
Lung Cancer; 2012 Dec; 78(3):234-8. PubMed ID: 23040415
[TBL] [Abstract][Full Text] [Related]
38. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer.
Cerfolio RJ; Bryant AS; Winokur TS; Ohja B; Bartolucci AA
Ann Thorac Surg; 2004 Dec; 78(6):1903-9; discussion 1909. PubMed ID: 15560998
[TBL] [Abstract][Full Text] [Related]
39. Impact of FDG-PET-induced treatment choices on long-term outcome in non-small cell lung cancer.
Wauters I; Stroobants S; De Leyn P; D'Hoore I; Nackaerts K; Dooms C; Vansteenkiste J
Respiration; 2010; 79(2):97-104. PubMed ID: 19420903
[TBL] [Abstract][Full Text] [Related]
40. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure.
Mac Manus MP; Hicks RJ; Matthews JP; Wirth A; Rischin D; Ball DL
Lung Cancer; 2005 Jul; 49(1):95-108. PubMed ID: 15949595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
